Discussing alpha-synuclein test results in Lewy body disease
Part of Brain & nervous system, Mental health clinical trials.
This study looks at how to tell people about their test results for alpha-synuclein, a protein linked to Lewy body disease (including Parkinson's disease and certain dementias). It aims to help people understand their diagnosis and the process of sharing these results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need to have access to a regular doctor or neurologist for ongoing care.
- You must be willing to get a skin biopsy or a spinal tap to test for alpha-synuclein, or have results from a recent test that you haven't been told about yet.
- If you are healthy (no symptoms), you must be in good overall health and have no other brain or nervous system conditions.
- If you have symptoms, you need a referral from a neurologist or movement disorder specialist, and you must have a caregiver who can help with the study.
- You must not be currently enrolled in another trial that has conflicting rules about sharing results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how brain function changes over time in people with Lewy body disease or Alzheimer's. Researchers will use memory tests, MRI scans, and EEG (a painless brain-wave recording) to track these changes, and you will need a family member or friend to help report on your daily life.
This trial follows people with probable Lewy body dementia over several years to see how the brain changes on MRI and on memory/thinking tests. It may help researchers understand disease progression and improve future care for Lewy body dementia.
This study is testing whether digital health tools (like wearable sensors) can better track symptoms of certain brain conditions (PSP, DLB, and MCI with Lewy bodies). It aims to improve monitoring and care for people with these conditions.
This trial looks at brain wave patterns (EEG) and nerve damage in people with Lewy body disease. It uses past data from a study called Alpha-Lewy-MA and a special test (RT-QuIC) to learn more about the disease.
This study tracks changes in people with Parkinson's disease, other movement disorders, or cognitive decline to find better ways to measure disease progression.
This study tests donanemab, an investigational drug designed to target amyloid proteins in the brain that may contribute to cognitive decline in people with early dementia with Lewy bodies. The trial aims to see if this treatment can slow cognitive decline and help preserve thinking and memory.
Hear when a new Lewy Body Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.